Synlogic Provides Corporate Update and Outlook for 2024
04. Januar 2024 07:00 ET
|
Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09. November 2023 07:00 ET
|
Synlogic, Inc.
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial...
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
29. September 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Phenylketonuria Market to Hit US$ 1,230.05 Million By 2030 | Latest Data Insights
07. September 2023 04:00 ET
|
CONSEGIC BUSINESS INTELLIGENCE PRIVATE LIMITED
New York, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The global Phenylketonuria Market is expected to witness significant growth at a CAGR of 5.2% during the forecast period of 2023-2030. This growth is...
Phenylketonuria Market to Exhibit Significant Growth, Assesses DelveInsight | Key Companies - BioMarin, Synlogic, PTC Therapeutics, Jnana Therapeutics, Homology Medicines
31. Juli 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Phenylketonuria Market to Exhibit Significant Growth, Assesses DelveInsight | Key Companies - BioMarin, Synlogic, PTC Therapeutics, Jnana...
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
11. Juli 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
08. Juni 2023 06:45 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will...
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
05. Juni 2023 06:45 ET
|
Synlogic, Inc.
Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in...
Global Phenylketonuria Market Size To Grow USD 1121.01 Billion by 2030 | CAGR of 6.2%
20. April 2023 07:45 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , April 20, 2023 (GLOBE NEWSWIRE) -- The Global Phenylketonuria Market Size is to grow from USD 610.3 million in 2022 to USD 1121.01 million by 2032, at a Compound Annual...
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
29. März 2023 06:40 ET
|
Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...